Back to search results

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

    Contact: Study coordinator (Dr Ursula Vogl) · Ursula.Vogl@eoc.ch · 091 811 84 63
    Contact: Study coordinator (Professor Dr. Med. Andrea Alimonti, Translational Scientific Lead Coordinator at the IOR) · andrea.alimonti@ior.usi.ch
    Contact: Principal Investigator (Dr Ursula Vogl)

  • Belfast Health and Social Care Trust, Belfast, United Kingdom

    Contact: Study coordinator (Dr Vicky Coyle) · v.coyle@qub.ac.uk · 02895048492
    Contact: Principal Investigator (Dr Vicky Coyle)

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

    Contact: Study coordinator (Dr Simon Pacey) · scp46@medschl.cam.ac.uk · 07712201563
    Contact: Principal Investigator (Dr Simon Pacey)

  • The Royal Marsden NHS Foundation Trust - Drug Development Unit, Sutton, United Kingdom

    Contact: Study coordinator (Professor Johann de Bono) · Johann.DeBono@icr.ac.uk · 02087224028
    Contact: Principal Investigator (Professor Johann de Bono)
Study leads

  • Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc

    Study Director

    Institute of Cancer Research, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)